Boceprevir PBS listed from 1 April

The Pharmaceutical Benefits Advisory Committee endorsed two new products, boceprevir and telaprevir, almost a year ago but their PBS listing was delayed because – as products costing taxpayers more than $10 million a year – they needed federal Cabinet sign-off.

In February Health Minister Tanya Plibersek said both products, normally costing an estimated $50,000 per patient without a rebate, would be listed. 

Last week sponsor MSD confirmed boceprevir (Victrelis, MSD) would be listed from 1 April. 

Professor Simone Strasser, chair of the

Latest

Trending